PRINCETON, N.J. and TEL AVIV, Israel, Nov. 24, 2025 /PRNewswire/ -- Made Scientific, Inc., a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO), and Cellergy Therapeutics Ltd., a biotechnology company pioneering first-in-class mitochondrial transplantation therapies, today announced a manufacturing partnership to advance Cellergy's mitochondrial therapy CLG-001 toward first-in-human clinical studies.

Under this collaboration, Cellergy Therapeutics will leverage Made Scientific's GMP manufacturing capabilities to implement and scale Cellergy's proprietary mitochondrial isolation and purification process. The work will support the production of clinical-grade CLG-001 for upcoming trials under Israel's Ministry of Health

See Full Page